|
|Section2= |Section3= }} NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo()quinoxaline-2,3-dione) is an AMPA receptor antagonist. NBQX blocks AMPA receptors in micromolar concentrations (~10–20 µM) and also blocks kainate receptors. In experiments, it is used to counter glutamate excitotoxicity.〔Pitt, D.; Werner, P.; Raine, C. S. (2000). "Glutamate excitotoxicity in a model of multiple sclerosis". ''Nat Med.'' 6 (1): 67–70.〕 NBQX was found to have anticonvulsant activity in rodent seizure models.〔Yamaguchi, S.; Donevan, S.D.; Rogawski, M.A. (1993). Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. ''Epilepsy Res.'' 15:179–184.〕 As the disodium salt, NBQX is soluble in water at high concentrations (at least up to 100 mM).〔(Product information at Tocris )〕 ==See also== * Quinoxalinedione 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「NBQX」の詳細全文を読む スポンサード リンク
|